Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A

Journal of Medicinal Chemistry

Volumn 57, Issue 3, 2014, Pages 759-769

  Schade, Dennis ^a,d   Kotthaus, Joscha ^a   Riebling, Lukas ^a   Kotthaus, Jürke ^a   Müller Fielitz, Helge ^b   Raasch, Walter ^b   Koch, Oliver ^d   Seidel, Nora ^c   Schmidtke, Michaela ^c   Clement, Bernd ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATION, ORAL; AMIDINES; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; DOGS; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; MALE; MOLECULAR DOCKING SIMULATION; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PRODRUGS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE;

EID: 84894094139     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401492x     Document Type: Article

References (46)

1. World Health Organization Influenza Fact Sheet 211; World Health Organization: Geneva, 2009; http://www.who.int/mediacentre/factsheets/fs211/en/.
2. Smith, G. J.; Vijaykrishna, D.; Bahl, J.; Lycett, S. J.; Worobey, M.; Pybus, O. G.; Ma, S. K.; Cheung, C. L.; Raghwani, J.; Bhatt, S.; Peiris, J. S.; Guan, Y.; Rambaut, A. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic Nature 2009, 459, 1122-1125
3. Novel Swine-Origin Influenza, A. V. I. T.; Dawood, F. S.; Jain, S.; Finelli, L.; Shaw, M. W.; Lindstrom, S.; Garten, R. J.; Gubareva, L. V.; Xu, X.; Bridges, C. B.; Uyeki, T. M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans N. Engl. J. Med. 2009, 360, 2605-2615
4. Webby, R. J.; Webster, R. G. Are we ready for pandemic influenza? Science 2003, 302, 1519-1522
5. Gao, R.; Cao, B.; Hu, Y.; Feng, Z.; Wang, D.; Hu, W.; Chen, J.; Jie, Z.; Qiu, H.; Xu, K.; Xu, X.; Lu, H.; Zhu, W.; Gao, Z.; Xiang, N.; Shen, Y.; He, Z.; Gu, Y.; Zhang, Z.; Yang, Y.; Zhao, X.; Zhou, L.; Li, X.; Zou, S.; Zhang, Y.; Li, X.; Yang, L.; Guo, J.; Dong, J.; Li, Q.; Dong, L.; Zhu, Y.; Bai, T.; Wang, S.; Hao, P.; Yang, W.; Zhang, Y.; Han, J.; Yu, H.; Li, D.; Gao, G. F.; Wu, G.; Wang, Y.; Yuan, Z.; Shu, Y. Human infection with a novel avian-origin influenza A (H7N9) virus N. Engl. J. Med. 2013, 368, 1888-1897
6. Das, K. Antivirals targeting influenza A virus J. Med. Chem. 2012, 55, 6263-6277
7. De Clercq, E. Antiviral agents active against influenza A viruses Nat. Rev. Drug Discovery 2006, 5, 1015-1025
8. Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P. A.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors J. Med. Chem. 1998, 41, 2451-2460
9. Miller, P. E.; Rambachan, A.; Hubbard, R. J.; Li, J.; Meyer, A. E.; Stephens, P.; Mounts, A. W.; Rolfes, M. A.; Penn, C. R. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study PloS One 2012, 7, e43491
10. Woods, J. M.; Bethell, R. C.; Coates, J. A.; Healy, N.; Hiscox, S. A.; Pearson, B. A.; Ryan, D. M.; Ticehurst, J.; Tilling, J.; Walcott, S. M.; Penn, C. R. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro Antimicrob. Agents Chemother. 1993, 37, 1473-1479
11. Yamashita, M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza Antimicrob. Agents Chemother. 2010, 21, 71-84
12. Kubo, S.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Yamashita, M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration Antimicrob. Agents Chemother. 2010, 54, 1256-1264
13. Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T. H.; Hutchison, T. L.; Elliott, A. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Laver, G. W.; Montgomery, J. A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design J. Med. Chem. 2000, 43, 3482-3486
14. Birnkrant, D.; Cox, E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza N. Engl. J. Med. 2009, 361, 2204-2207
15. Arya, V.; Carter, W. W.; Robertson, S. M. The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir Clin. Pharmacol. Ther. 2010, 88, 587-589
16. Sheu, T. G.; Deyde, V. M.; Okomo-Adhiambo, M.; Garten, R. J.; Xu, X.; Bright, R. A.; Butler, E. N.; Wallis, T. R.; Klimov, A. I.; Gubareva, L. V. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008 Antimicrob. Agents Chemother. 2008, 52, 3284-3292
17. Nguyen, H. T.; Fry, A. M.; Gubareva, L. V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods Antivir. Ther. 2012, 17, 159-173
18. Davies, B. E. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations J. Antimicrob. Chemother. 2010, 65 (Suppl 2) ii5-ii10
19. Cass, L. M.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers Clin. Pharmacokinet. 1999, 36 (Suppl 1) 1-11
20. Feng, E.; Ye, D.; Li, J.; Zhang, D.; Wang, J.; Zhao, F.; Hilgenfeld, R.; Zheng, M.; Jiang, H.; Liu, H. Recent advances in neuraminidase inhibitor development as anti-influenza drugs ChemMedChem 2012, 7, 1527-1536
21. Li, W.; Escarpe, P. A.; Eisenberg, E. J.; Cundy, K. C.; Sweet, C.; Jakeman, K. J.; Merson, J.; Lew, W.; Williams, M.; Zhang, L.; Kim, C. U.; Bischofberger, N.; Chen, M. S.; Mendel, D. B. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071 Antimicrob. Agents Chemother. 1998, 42, 647-653
22. Shie, J. J.; Fang, J. M.; Wang, S. Y.; Tsai, K. C.; Cheng, Y. S.; Yang, A. S.; Hsiao, S. C.; Su, C. Y.; Wong, C. H. Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity J. Am. Chem. Soc. 2007, 129, 11892-11893
23. Cheng, T. J.; Weinheimer, S.; Tarbet, E. B.; Jan, J. T.; Cheng, Y. S.; Shie, J. J.; Chen, C. L.; Chen, C. A.; Hsieh, W. C.; Huang, P. W.; Lin, W. H.; Wang, S. Y.; Fang, J. M.; Hu, O. Y.; Wong, C. H. Development of oseltamivir phosphonate congeners as anti-influenza agents J. Med. Chem. 2012, 55, 8657-86570
24. Liu, K. C.; Lee, P. S.; Wang, S. Y.; Cheng, Y. S.; Fang, J. M.; Wong, C. H. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir Bioorg. Med. Chem. 2011, 19, 4796-4802
25. Miller, J. M.; Dahan, A.; Gupta, D.; Varghese, S.; Amidon, G. L. Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir Mol. Pharmaceutics 2010, 7, 1223-1234
26. Gupta, D.; Varghese Gupta, S.; Dahan, A.; Tsume, Y.; Hilfinger, J.; Lee, K. D.; Amidon, G. L. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue Mol. Pharmacol. 2013, 10, 512-522
27. Froehlich, A. K.; Girreser, U.; Clement, B. Metabolism of N-hydroxyguanidines (N-hydroxydebrisoquine) in human and porcine hepatocytes: reduction and formation of glucuronides Drug Metab. Dispos. 2005, 33, 1532-1537
28. Clement, B.; Schultze-Mosgau, M. H.; Wohlers, H. Cytochrome P450 dependent N-hydroxylation of a guanidine (debrisoquine), microsomal catalysed reduction and further oxidation of the N-hydroxy-guanidine metabolite to the urea derivative. Similarity with the oxidation of arginine to citrulline and nitric oxide Biochem. Pharmacol. 1993, 46, 2249-2267
29. Schade, D.; Kotthaus, J.; Klein, N.; Kotthaus, J.; Clement, B. Prodrug design for the potent cardiovascular agent Nomega-hydroxy- l -arginine (NOHA): synthetic approaches and physicochemical characterization Org. Biomol. Chem. 2011, 9, 5249-5259
30. Clement, B.; Demesmaeker, M.; Linne, S. Microsomal catalyzed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz Chem. Res. Toxicol. 1996, 9, 682-688
31. Shearer, B. G.; Oplinger, J. A.; Lee, S. S -2-Naphthylmethyl Thioacetimidste Hydrobromide: A New Odorless Reagent For The Mild Synthesis Of Substituted Acetamidines Tetrahedron Lett. 1997, 38, 179-182
32. Zhang, J.; Curran, D. P. Stereoselective synthesis of 1,2-diols by the cycloadditive strategy: total synthesis of (±)-exo-brevicomin and (±)- and (-)-pestalotin J. Chem. Soc. Perkin 1 1991, 11, 2627-2631
33. Kirchmair, J.; Rollinger, J. M.; Liedl, K. R.; Seidel, N.; Krumbholz, A.; Schmidtke, M. Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode Future Med. Chem. 2011, 3, 437-450
34. Bauer, K.; Richter, M.; Wutzler, P.; Schmidtke, M. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006 Antivir. Res. 2009, 82, 34-41
35. Grienke, U.; Schmidtke, M.; Kirchmair, J.; Pfarr, K.; Wutzler, P.; Durrwald, R.; Wolber, G.; Liedl, K. R.; Stuppner, H.; Rollinger, J. M. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai J. Med. Chem. 2010, 53, 778-786
36. Samson, M.; Pizzorno, A.; Abed, Y.; Boivin, G. Influenza virus resistance to neuraminidase inhibitors Antivir. Res. 2013, 98, 174-185
37. He, G.; Massarella, J.; Ward, P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802 Clin. Pharmacokinet. 1999, 37, 471-484
38. Eisenberg, E. J.; Bidgood, A.; Cundy, K. C. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104 Antimicrob. Agents Chemother. 1997, 41, 1949-1952
39. Clement, B.; Lopian, K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug Drug Metab. Dispos. 2003, 31, 645-651
40. Kotthaus, J.; Hungeling, H.; Reeh, C.; Schade, D.; Wein, S.; Wolffram, S.; Clement, B. Synthesis and biological evaluation of L-valine-amidoximeesters as double prodrugs of amidines Bioorg. Med. Chem. 2011, 19, 1907-1914
41. Steudel, R.; Schenk, P. W. Hydroxylamine base was set free from its hydrochloride salt with sodium ethanolate. In Handbuch der Präparativen Anorganischen Chemie, 3 rd ed.; Brauer, G., Ed.; Ferdinand Enke Verlag: Stuttgart, 1975; Vol. 1, p 464.
42. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera - a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
43. Molecular Operating Environment (MOE); Chemical Computing Group Inc: Montreal; http://www.chemcomp.com. (accessed September 9, 2013).
44. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
45. Reed, L.; Muench, H. A simple method of estimating fifty percent endpoints Am. J. Hyg. 1938, 27, 493-497
46. Schmidtke, M.; Schnittler, U.; Jahn, B.; Dahse, H.; Stelzner, A. A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1 J. Virol. Methods 2001, 95, 133-143